drugset / Trial / NCT05105698

Food-effect Bioavailability of Gemigliptin and Dapagliflozin 50/10 mg

NCT05105698

Phase 1 Unknown 28 enrolled LG Chem
RandomizedCrossoverOpen-labelTreatment

Summary

A Randomized, Open-label, Single-dose, Two-way Crossover Study to Investigate Food-effect Bioavailability of Gemigliptin and Dapagliflozin 50/10 mg Fixed Dose Combination Film-coated Tablet under Fed and Fasting Conditions in Healthy Volunteers

Timeline

Start
2022-01-01
Primary completion
2022-02-28
Completion
2022-09-30

Drugs

EvaluationDrugModalityDoseRoute
Subject Dapagliflozin Small molecule 10 mg Oral
Subject Gemigliptin Small molecule 50 mg Oral

Indications

No indication recorded.